Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Gradient Investments LLC

Gradient Investments LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 23.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,052 shares of the biopharmaceutical company’s stock after buying an additional 203 shares during the quarter. Gradient Investments LLC’s holdings in Gilead Sciences were worth $65,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Landmark Wealth Management LLC purchased a new position in Gilead Sciences during the 1st quarter worth approximately $30,000. Joseph P. Lucia & Associates LLC purchased a new position in Gilead Sciences during the 1st quarter worth approximately $25,000. TFO TDC LLC purchased a new position in Gilead Sciences during the 1st quarter worth approximately $27,000. Cornerstone Advisory LLC purchased a new position in Gilead Sciences during the 4th quarter worth approximately $34,000. Finally, Mystic Asset Management Inc. purchased a new position in Gilead Sciences during the 4th quarter worth approximately $33,000. 78.58% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 1.9 %

GILD stock opened at $64.58 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.30. Gilead Sciences, Inc. has a 1 year low of $57.17 and a 1 year high of $74.12. The company has a fifty day simple moving average of $63.11 and a 200 day simple moving average of $61.97. The firm has a market cap of $80.94 billion, a PE ratio of 19.69, a PEG ratio of 0.63 and a beta of 0.31.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Thursday, September 15th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 4.52%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s payout ratio is presently 89.02%.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Truist Financial lifted their price objective on shares of Gilead Sciences from $71.00 to $76.00 and gave the stock a “hold” rating in a research report on Thursday, September 15th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Monday, August 15th. SVB Leerink restated a “market perform” rating on shares of Gilead Sciences in a report on Thursday, September 15th. StockNews.com cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 17th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, July 12th. They set a “neutral” rating and a $70.00 price target on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $73.53.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.